Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid®) (CR2) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): A phase II trial.

Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedP.O. box 52013008 AE RotterdamTel: +31 10 7041560Fax: +31 10 7041028e-mail: hdc@erasmusmc.nl0 sites62 target enrollmentTBD

ConditionsAdvanced previously untreated Chronic Lymphocytic Leukemia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Advanced previously untreated Chronic Lymphocytic Leukemia
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedP.O. box 52013008 AE RotterdamTel: +31 10 7041560Fax: +31 10 7041028e-mail: hdc@erasmusmc.nl
Enrollment: 62
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Eligibility Criteria

Inclusion Criteria

•1\. Diagnosis of CLL without prior treatment;
•2\. Patients with symptomatic (according to IWCLL guidelines) stage A or stage B or stage C;

Exclusion Criteria

•1\. Patients that are unable or unwilling to adhere to the requirements of the Lenalidomide Pregnancy Prevention Risk Management Plan;
•2\. Intolerance of exogenous protein administration;